Triple motif proteins 19 and 38 correlated with treatment responses and HBsAg clearance in HBeAg-negative chronic hepatitis B patients during peg-IFN-α therapy.

Publisher: BioMed Central Country of Publication: England NLM ID: 101231645 Publication Model: Electronic Cited Medium: Internet ISSN: 1743-422X (Electronic) Linking ISSN: 1743422X NLM ISO Abbreviation: Virol J Subsets: MEDLINE

Original Publication: [London] : BioMed Central, 2004-

Hepatitis B Surface Antigens* ; Hepatitis B, Chronic*; Humans ; Hepatitis B e Antigens ; Antiviral Agents/therapeutic use ; Prospective Studies ; DNA, Viral ; Leukocytes, Mononuclear ; Treatment Outcome ; Interferon-alpha/therapeutic use ; Transcription Factors ; Polyethylene Glycols/therapeutic use ; RNA, Messenger ; Recombinant Proteins/therapeutic use

Objective: To investigate whether the expression of triple motif protein 19/38 (TRIM19/38) mRNA in peripheral blood mononuclear cells (PBMCs) of HBeAg-negative chronic hepatitis B virus (HBV) carriers is associated with the response to pegylated interferon alpha (peg-IFN-α) treatment and HBsAg clearance.
Methods: In this prospective study, HBeAg-negative chronic HBV carriers treated with peg-IFN-α completed 48 weeks of follow-up. After treatment with peg-IFN-α, the patients were divided into responders (R group) and nonresponders (NR group) according to the changes in HBV DNA and HBsAg levels at week 48 of treatment. According to whether serum HBsAg loss or seroconversion occurred, the patients were divided into a serological response group (SR group) and a nonserological response group (NSR group). The level of TRIM19/38 mRNA in PBMCs was detected by real-time fluorescence quantitative PCR. The diagnostic performance of TRIM19/38 was analysed by calculating the receiver operating characteristic (ROC) curve and area under the ROC curve (AUC).
Results: 43 HBeAg-negative chronic HBV carriers, 35 untreated CHB patients and 19 healthy controls were enrolled in this study. We found that TRIM19/38 mRNA levels were significantly lower in untreated CHB patients than in healthy controls. In HBeAg-negative chronic HBV carriers who underwent prospective follow-up, TRIM19/38 mRNA levels were negatively correlated with HBV DNA and ALT at baseline. Among the patients treated with peg-IFN-α, 16 patients achieved a treatment response (R group) and 27 patients did not achieve a treatment response (NR group). Compared with baseline, HBsAg levels in the R group decreased significantly at 12 and 24 weeks of treatment; at the early stage of peg-IFN-α treatment, the dynamic changes in TRIM19/38 mRNA levels in the R and NR groups were different, and the TRIM19/38 mRNA levels in the R group were significantly higher than those in the NR group, especially at 24 weeks of treatment. ROC curve analysis showed that the changes in mRNA levels of TRIM19 and TRIM38 predicted the treatment response, with AUCs of 0.694 and 0.757, respectively. Among the patients treated with peg-IFN-α, 11 patients achieved a serological response (SR group) and 32 patients did not achieve a serological response (NSR group). Compared with baseline, HBsAg levels in the SR group decreased significantly at 12 and 24 weeks of treatment; TRIM19/38 mRNA levels were significantly higher in the SR group than in the NSR group at week 24.
Conclusion: The higher level of TRIM19/38 mRNA in PBMCs of HBeAg-negative chronic HBV carriers may be related to the early treatment effect of peg-IFN-α and HBsAg clearance. TRIM19 and TRIM38 have clinical significance in predicting virological response and guiding treatment regimens.
(© 2023. The Author(s).)

Gut. 2015 Aug;64(8):1314-26. (PMID: 25670809)
Hepatology. 2020 Sep;72(3):1142-1144. (PMID: 32502295)
Clin Liver Dis (Hoboken). 2013 Mar 01;2(1):18-20. (PMID: 30992814)
Hepatology. 2017 Oct;66(4):1058-1066. (PMID: 28407271)
Cell Mol Immunol. 2018 Mar;15(3):272-281. (PMID: 28194021)
Genes Cancer. 2011 Jan;2(1):10-9. (PMID: 21779477)
J Virol. 2022 Jul 13;96(13):e0054622. (PMID: 35695580)
Lancet. 2014 Dec 6;384(9959):2053-63. (PMID: 24954675)
EMBO Mol Med. 2011 Sep;3(9):513-27. (PMID: 21826793)
Virology. 2023 Feb;579:84-93. (PMID: 36623352)
J Virol. 2013 Jan;87(1):257-72. (PMID: 23077300)
Ann N Y Acad Sci. 1980;350:130-44. (PMID: 6165268)
Hepatol Int. 2007 Jun;1(2):311-5. (PMID: 19669355)
PLoS Pathog. 2015 Mar 26;11(3):e1004785. (PMID: 25812002)
Clin Res Hepatol Gastroenterol. 2017 Sep;41(4):386-398. (PMID: 28236535)
Front Biosci (Landmark Ed). 2011 Jun 01;16(8):2910-20. (PMID: 21622212)
Immunology. 2018 Feb;153(2):171-178. (PMID: 28921535)
J Viral Hepat. 2016 Nov;23(11):905-911. (PMID: 27375231)
Front Cell Infect Microbiol. 2021 Nov 18;11:790036. (PMID: 34869083)
J Immunol. 2012 Jun 1;188(11):5311-8. (PMID: 22539786)
Gastroenterology. 2010 May;138(5):1747-54. (PMID: 20114048)
J Gastroenterol Hepatol. 1997 Oct;12(9-10):S218-22. (PMID: 9407340)
Lancet Gastroenterol Hepatol. 2019 Jul;4(7):545-558. (PMID: 30981686)
Hepatology. 2018 Apr;67(4):1560-1599. (PMID: 29405329)
Cell Mol Immunol. 2017 Apr;14(4):331-338. (PMID: 28194022)
N Engl J Med. 2004 Mar 11;350(11):1118-29. (PMID: 15014185)
J Hepatol. 2017 Aug;67(2):370-398. (PMID: 28427875)

Keywords: Chronic carriers; Hepatitis B virus; TRIM19; TRIM38; Virological response; peg-IFN-α

0 (Hepatitis B Surface Antigens)
0 (Hepatitis B e Antigens)
0 (Antiviral Agents)
0 (DNA, Viral)
0 (Interferon-alpha)
0 (Transcription Factors)
3WJQ0SDW1A (Polyethylene Glycols)
0 (RNA, Messenger)
0 (Recombinant Proteins)

Date Created: 20230720 Date Completed: 20231023 Latest Revision: 20231103

20240513

PMC10360334

10.1186/s12985-023-02119-7

37475028